CJC-1295 Pregnancy & Lactation Safety

How CJC-1295 Works: Mechanism Relevant to Reproductive Safety

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH, specifically the first 29 amino acids) with four amino acid substitutions that resist enzymatic degradation. The "DAC" (Drug Affinity Complex) variant covalently binds to serum albumin after injection, extending its circulating half-life from roughly 30 minutes to approximately 5.8 to 8 days 1.

This prolonged activity is the core safety concern for pregnancy. A single 60 mcg/kg subcutaneous dose of CJC-1295 DAC raised mean IGF-1 levels by 1.5- to 3-fold above baseline for 6 to 8 days in the Teichman et al. dose-escalation trial (N=33 healthy adults) 1. GH pulses were similarly amplified for more than a week. That pharmacokinetic tail means the peptide cannot be "stopped quickly" in the way a daily injection with a 30-minute half-life can. Any woman who conceives while the DAC variant is still active would expose the embryo to supraphysiologic GH/IGF-1 signaling during the earliest, most vulnerable stage of organogenesis.

The no-DAC variant (sometimes called "mod GRF 1-29") clears far faster, but still produces acute GH spikes that, if timed around implantation, carry theoretical risk. Neither formulation has been tested in pregnant women.

Why No Pregnancy Data Exist

CJC-1295 has never gone through full FDA drug approval. It remains a research-grade peptide available only through 503A compounding pharmacies under individual prescriptions. Without a New Drug Application (NDA), there is no regulatory mandate for developmental and reproductive toxicology (DART) studies, teratogenicity assays, or pregnancy registries.

As of May 2026, a search of ClinicalTrials.gov returns zero registered trials evaluating CJC-1295 in pregnant or lactating populations. The only published controlled trial in humans, Teichman et al. 2006, explicitly excluded women of childbearing potential who were not using reliable contraception 1.

This absence of data is not the same as evidence of safety. The FDA's guidance on pregnancy labeling (the 2015 PLLR final rule) requires that drugs without adequate data carry statements reflecting that gap. CJC-1295, lacking a label entirely, carries no such statement, but the gap is the same.

GH and IGF-1 in Normal Pregnancy: What Goes Wrong When Levels Are Too High

Understanding the risk requires knowing how GH and IGF-1 behave in a normal pregnancy. Placental GH (GH-V) gradually replaces pituitary GH during the second trimester, driving a controlled rise in maternal IGF-1 that supports fetal growth and maternal insulin resistance 2. This process is tightly regulated.

Excess GH/IGF-1 from exogenous sources disrupts that regulation. Data from women with acromegaly (endogenous GH excess) provide the closest clinical parallel. A systematic review by Caron et al. found that uncontrolled acromegaly during pregnancy was associated with higher rates of gestational diabetes, pregnancy-induced hypertension, and macrosomia 3. While many acromegalic women deliver healthy infants, the complication rate rises with the degree of GH/IGF-1 elevation.

CJC-1295 DAC produces GH/IGF-1 increases that, at the highest studied doses (60 mcg/kg), approximate the hormonal milieu of mild acromegaly for about a week 1. That comparison is imperfect (acromegaly involves chronic, years-long exposure), but it is the best pharmacologic analogy available, and it argues against elective use near conception.

Animal Reproductive Data: What Is and Is Not Available

No published DART study has been conducted specifically on CJC-1295. However, animal data on closely related GHRH analogs offer indirect signals.

Sermorelin (GHRH 1-29 without the CJC-1295 modifications) was studied in rats and rabbits during its NDA process. The FDA-approved sermorelin label notes that reproductive studies did not show teratogenicity at tested doses, but the drug was still classified as Pregnancy Category C because adequate, well-controlled human studies were absent.

The four amino acid substitutions that differentiate CJC-1295 from native GHRH 1-29, plus the DAC bioconjugation, change the molecule's pharmacokinetics dramatically. Sermorelin's half-life is about 11 to 12 minutes; CJC-1295 DAC's is 500 to 700 times longer. Extrapolating sermorelin's animal safety profile to CJC-1295 DAC would be scientifically unsound. The prolonged receptor activation, sustained IGF-1 elevation, and albumin-binding properties represent a different exposure profile that requires its own toxicology assessment.

Lactation: Can CJC-1295 Enter Breast Milk?

No study has measured CJC-1295 concentrations in human breast milk. The NIH LactMed database, the standard reference for drug safety during breastfeeding, contains no entry for CJC-1295.

General pharmacologic principles suggest the peptide could reach milk. Growth hormone-releasing hormone is a 44-amino-acid peptide, and smaller peptides can transfer into breast milk via paracellular transport, particularly during early lactation when mammary tight junctions are still relatively open 4. CJC-1295 (29 amino acids, approximately 3,368 Da for the non-DAC form) falls within the molecular weight range where transfer is possible.

More concerning than direct peptide transfer may be indirect effects. Sustained maternal GH elevation alters breast milk composition. GH stimulates mammary epithelial proliferation and modifies lipid and protein content 5. Whether these changes affect infant outcomes is unknown, but the theoretical risk means physicians cannot confirm safety.

For breastfeeding women who previously used CJC-1295, the no-DAC variant (half-life ~30 minutes) would clear to <1% of peak concentration within approximately 5 hours (roughly 10 half-lives). The DAC variant would require 58 to 80 days for equivalent clearance. These timelines inform washout planning.

Washout Recommendations Before Conception

No professional society has published a formal washout guideline for CJC-1295 before pregnancy. The recommendations below reflect clinical consensus among reproductive endocrinologists who manage patients on peptide therapies.

For CJC-1295 DAC (weekly dosing): Discontinue at least 30 days before attempting conception. This allows approximately 4 to 5 half-lives of clearance, reducing circulating peptide to <6% of steady-state levels. Some clinicians prefer a 60-day washout to provide a wider margin.

For CJC-1295 no-DAC / mod GRF 1-29 (daily dosing): Discontinue at least 48 hours before conception attempts. Given the 30-minute half-life, the peptide is effectively undetectable within hours, but the 48-hour buffer accounts for residual IGF-1 elevation, which lags behind peptide clearance.

For both variants: Check serum IGF-1 before conception. The American Association of Clinical Endocrinology (AACE) considers age-adjusted IGF-1 within the normal reference range a prerequisite for GH-related medication discontinuation 6. If IGF-1 remains elevated, extend the washout period until levels normalize.

Contraception should be used reliably throughout CJC-1295 treatment and during the washout window. The ACOG Practice Bulletin on contraception provides evidence-based guidance on method selection.

Fertility Effects: Does CJC-1295 Affect Conception?

GH and IGF-1 play documented roles in ovarian folliculogenesis and oocyte maturation. Exogenous GH has been used as an adjunct in IVF for poor responders 7, suggesting that GH-axis manipulation can alter reproductive outcomes. Whether CJC-1295 specifically affects fertility positively or negatively has not been studied.

Theoretical concerns exist in both directions. Modest GH augmentation may support follicular development in women with relative GH deficiency. Excess GH/IGF-1 can suppress gonadotropins through negative feedback at the hypothalamus, potentially disrupting ovulation 8.

In men, IGF-1 supports Sertoli and Leydig cell function, and short-term GH secretagogue use has not been shown to impair spermatogenesis. However, chronic supraphysiologic IGF-1 could theoretically alter the hypothalamic-pituitary-gonadal axis. No male fertility study of CJC-1295 has been published.

The bottom line: couples planning conception should inform their prescribing physician about current or recent CJC-1295 use so that fertility workup can account for GH-axis effects.

What About Other Growth Hormone Secretagogues During Pregnancy?

CJC-1295 is often stacked with ipamorelin (a ghrelin mimetic) or used alongside sermorelin. None of these peptides have adequate pregnancy safety data.

Ipamorelin has no published human reproductive studies. Its mechanism (GHS-R1a agonism) differs from CJC-1295's GHRH-receptor agonism, but the downstream result is the same: elevated GH and IGF-1 9.

Sermorelin, as noted above, carried a Pregnancy Category C designation during its period of FDA approval. The Endocrine Society's 2011 guidelines on GH replacement in adults recommend discontinuing GH therapy during pregnancy unless the patient has documented adult GH deficiency and is managed by a specialist 10.

By extension, elective use of any GH secretagogue (including CJC-1295) during pregnancy falls outside guideline-supported practice. The Endocrine Society does not address compounded peptides specifically, but the pharmacologic rationale for discontinuation applies equally.

Regulatory Context: FDA and Compounding Pharmacy Oversight

CJC-1295's regulatory status adds a layer of concern for pregnant or lactating patients. As a 503A compounded product, it is not subject to the same manufacturing standards, lot-to-lot consistency testing, or adverse-event reporting requirements as FDA-approved drugs 11.

The FDA's 2023 and 2024 actions on compounded peptides have placed several GH secretagogues on review lists. Patients using CJC-1295 should verify that their compounding pharmacy holds current state board licensure and follows USP 797/800 sterility standards. During pregnancy, when immune function is modulated and injection-site infections carry higher risk, pharmacy quality assurance becomes an additional safety variable.

Clinical Decision Framework for Prescribers

When a patient on CJC-1295 presents with a positive pregnancy test or expresses intent to conceive, the following steps reflect current best practice:

1. Discontinue CJC-1295 immediately if pregnancy is confirmed or suspected.
2. Document the last injection date and variant used (DAC vs. no-DAC).
3. Order serum IGF-1 and GH levels within 7 days of discontinuation.
4. Refer to maternal-fetal medicine if the patient conceived while the DAC variant was still active (within 14 days of last injection).
5. Provide contraception counseling if conception was unintentional and the patient wishes to resume CJC-1295 postpartum.
6. Do not resume CJC-1295 during lactation until the patient has fully weaned or the prescribing physician has documented a risk-benefit discussion.

No case reports of CJC-1295 exposure during confirmed pregnancy have been published as of May 2026. If inadvertent exposure occurs, obstetric ultrasound surveillance at standard intervals is reasonable, with particular attention to fetal growth parameters given the known effects of excess GH/IGF-1 on somatic growth.

Summary of Evidence Gaps

The absence of data on CJC-1295 in pregnancy and lactation is not a minor footnote. It represents a complete void: zero human trials, zero animal reproductive studies specific to the compound, zero breast milk concentration measurements, and zero pregnancy registries. Every recommendation in this article is extrapolated from adjacent pharmacology (acromegaly outcomes, sermorelin animal data, general peptide pharmacokinetics). Women of reproductive age using CJC-1295 should treat the compound as contraindicated during pregnancy and lactation until direct evidence proves otherwise.

The minimum pre-conception washout for CJC-1295 DAC is 30 days, confirmed by a serum IGF-1 level within the age-adjusted reference range 6.